National Institute for Infectious Diseases 'Lazzaro Spallanzani', Via Portuense 292, 00149 Rome, Italy.
Department of Molecular Medicine, 'Sapienza' University, Viale di Porta Tiburtina 28, 00185 Rome, Italy.
Int J Antimicrob Agents. 2015 Feb;45(2):111-2. doi: 10.1016/j.ijantimicag.2014.09.001. Epub 2014 Sep 6.
Hepatitis C virus (HCV), identified approximately 25 years ago, is recognised as the cause of several clinical conditions besides chronic hepatitis. New compounds with direct antiviral activity have recently been introduced. These drugs promise to outdo old therapies based on interferon and ribavirin both in terms of improved safety and virological response. In fact, these drugs may pave the way to complete eradication of the disease. However, their actual price is exceedingly high and a strategy is necessary to guarantee wide and sustainable access to new therapies.
丙型肝炎病毒（HCV）大约在 25 年前被发现，除了慢性肝炎外，它还被认为是引起多种临床疾病的原因。最近引入了具有直接抗病毒活性的新型化合物。这些药物在安全性和病毒学应答方面都优于基于干扰素和利巴韦林的旧疗法，这是有希望的。事实上，这些药物可能为彻底消除这种疾病铺平道路。然而，它们的实际价格非常高，因此有必要制定一种策略来保证广泛和可持续地获得新的治疗方法。
